title: NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma.
abstract: Hepatocellular carcinoma (HCC) is currently the third leading cause of cancer mortality and a common poor-prognosis malignancy due to postoperative recurrence and metastasis. There is a significant correlation between chronic hepatitis B virus (HBV) infection and hepatocarcinogenesis. As the first line of host defense against viral infections and tumors, natural killer (NK) cells express a large number of immune recognition receptors (NK receptors (NKRs)) to recognize ligands on hepatocytes, liver sinusoidal endothelial cells, stellate cells and Kupffer cells, which maintain the balance between immune response and immune tolerance of NK cells. Unfortunately, the percentage and absolute number of liver NK cells decrease significantly during the development and progression of HCC. The abnormal expression of NK cell receptors and dysfunction of liver NK cells contribute to the progression of chronic HBV infection and HCC and are significantly associated with poor prognosis for liver cancer. In this review, we focus on the role of NK cell receptors in anti-tumor immune responses in HCC, particularly HBV-related HCC. We discuss specifically how tumor cells evade attack from NK cells and how emerging understanding of NKRs may aid the development of novel treatments for HCC. Novel mono- and combination therapeutic strategies that target the NK cell receptor-ligand system may potentially lead to successful and effective immunotherapy in HCC.Cellular & Molecular Immunology advance online publication, 6 October 2014; doi:10.1038/cmi.2014.91.
authors.affiliation: Institute of Immunology, School of Life Sciences, University of Science and Technology of China, Hefei, China.
authors.forename: Cheng
authors.initials: C
authors.lastname: Sun
authors.affiliation: Institute of Immunology, School of Life Sciences, University of Science and Technology of China, Hefei, China.
authors.forename: Haoyu
authors.initials: H
authors.lastname: Sun
authors.affiliation: Institute of Immunopharmacology and Immunotherapy, School of Pharmaceutical Sciences, Shandong University, Jinan, China.
authors.forename: Cai
authors.initials: C
authors.lastname: Zhang
authors.affiliation: Institute of Immunology, School of Life Sciences, University of Science and Technology of China, Hefei, China.
authors.forename: Zhigang
authors.initials: Z
authors.lastname: Tian
mesh_terms: D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000276:immunology* / Q000628:therapy; D003602:Cytotoxicity, Immunologic; D005786:Gene Expression Regulation; D019694:Hepatitis B, Chronic / Q000276:immunology*; D006706:Homeostasis; D006801:Humans; D007167:Immunotherapy; D007694:Killer Cells, Natural / Q000276:immunology* / Q000821:virology; D008113:Liver Neoplasms / Q000209:etiology / Q000276:immunology* / Q000628:therapy; D058990:Molecular Targeted Therapy; D009362:Neoplasm Metastasis; D055607:Receptors, Natural Killer Cell / Q000235:genetics / Q000378:metabolism*; D012008:Recurrence; D019139:Tumor Escape
chemical_list: D055607:Receptors, Natural Killer Cell